Antibodies

#Antibodies #Gene therapy

Researchers develop new method for safer AAV gene therapies

Researchers at the HUN-REN Research Centre for Natural Sciences (HUN-REN TTK) have developed a new method for detecting neutralising antibodies (Nabs), offering the potential for safer and more successful AAV gene therapies.  The novel ‘Constant Serum Concentration’ (CSC) assay, published in the journal Nature Gene Therapy, correctly… Read More

#News

T cell attacking a cancer cell
#Antibodies #Immunotherapy #Oncology #Phase I trial #Rockefeller University

Immunotherapy drug eliminates aggressive cancers

A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink.  CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells.  … Read More

#Cancer Research #News #Trending News

Artificial intelligence
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Clinical trial design #Clinical trials #Start-ups

New podcast: Innovative applications of AI in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More

#News

Antibody
#Antibodies #argenx #Biology #Biotechnology #Drug development #Drug discovery #Muscles

argenx advances ARGX-119 in congenital myasthenic syndromes 

argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More

#News

Antibodies
#Absci #Antibodies #Biologics #Biopharmaceuticals #Clinical trials

Absci becomes clinical-stage company with clinical trial initiation

Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101. ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform. “We are excited to advance ABS-101 into Phase I clinical trials,”… Read More

#News

#Antibodies #Cell analysis #Cell therapy #Drug discovery #Single-cell analysis

How real-time analysis of single cells can advance drug discovery  

DDW Editor Reece Armstrong speaks to Vikram Devgan, PhD, VP of Global Marketing and Product Management, Bruker Cellular Analysis, about how real-time access to single cells can drive functional insights.   RA: How has single-cell research evolved over the past two decades?  VD: Single-cell research has transitioned from immunophenotyping via flow… Read More

#Exclusive Content

Human antibodies
#Antibodies #Epsilogen #Mergers and acquisitions #Oncology #Therapeutic Antibodies

Acquisition creates leading pan-isotype cancer antibody company

Epsilogen has completed the acquisition of TigaTx, a biotechnology company developing engineered immunoglobulin A (IgA) antibodies.  As a result, US-based TigaTx will become a wholly owned subsidiary of Epsilogen. Dr Sonia Gulati, a Principal at Global BioAccess Fund, has joined the Epsilogen Board of Directors.  Epsilogen CEO Tim Wilson said:… Read More

#Business & Investment #News

Meet The Exhibitor
#AI / data analytics / healthtech / informatics #Antibodies #Cancer research #Career #From the top #Genetics / genomics #Interview #Meet the Researcher #Oncology #Research and development #Sitting Down With #Women in STEM

New podcast: Getting to know key drug discovery leaders

This is the latest episode of the free DDW narrated podcast, titled “Getting to know key drug discovery leaders”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Sitting down with… Neil Dhawan”, “Meet the researcher: Giusy Di Conza, iOnctura”… Read More

#News

Therapeutic antibodies
#Antibodies #Chromatography #Drug discovery #Therapeutic Antibodies

The aggregation challenge: Measuring stability in therapeutic antibodies

Salma Jalal, Market Development Manager at Refeyn, looks at the need for and challenges of measuring antibody aggregation and discusses the ideal requirements of analytical tools to support it.  Antibody therapies have cemented their place in modern healthcare, offering powerful, targeted treatments for cancers, autoimmune disorders, infectious diseases and beyond. Read More

#Exclusive Content

Therapeutic antibodies
#Alzheimer's #Antibodies #Cancer #Covid-19 #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies #Rare disease #Therapeutic Antibodies

Podcast: Where is the innovation in the therapeutic antibody market?

This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More

#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Drivers and challenges in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Monoclonal antibody
#Antibodies #Drug discovery #Immunology / Virology & Vaccines #Therapeutic Antibodies

Antibody therapies: A core technology of the past, present, and the future

Jeff Fischer, President of Longhorn Vaccines & Diagnostics, discusses the evolution of antibody therapies from early serum treatments to targeted monoclonal antibodies, their impact on disease prevention and treatment, and the growing acceptance of antibody-based alternatives to traditional vaccines. Antibody therapy has been used to prevent and treat disease for over… Read More

#Exclusive Content

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Therapeutic antibody innovation

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar highlights innovation in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Monoclonal antibodies
#Antibodies #Biotechnology #Collaboration #Drug development #Drug discovery #Pierre Fabre Laboratories #RedRidge

Pharma/biotech biparatopic antibody collaboration agreed

Pierre Fabre Laboratories and RedRidge have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories’ innovation strategy, the partnership’s therapeutic focus will be on precision oncology as well as dermatology and rare diseases. Read More

#News

Bispecific antibodies
#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

Download the Article: The discovery and evolution of antibody formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This Article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent F1P HF as an alternative strategy for isolating… Read More

#News